BioCentury | Feb 18, 2008
Strategy

Functional GI compounds

...serotonin (5-HT4) receptor agonist/(5-HT3) receptor antagonist Serotonin (5-HT3) receptor; serotonin (5-HT4) receptor IBS Ph II Gastrotech/Eli...
BioCentury | Feb 4, 2008
Company News

Gastrotech, Eli Lilly deal

...Lilly granted Gastrotech exclusive, worldwide rights to GTP-010 to treat irritable bowel syndrome (IBS) and functional...
...undisclosed equity stake in Gastrotech and is eligible for royalties. Further terms were not disclosed. Gastrotech Pharma A/S...
BioCentury | Sep 4, 2006
Company News

ReceptIcon management update

...ApS , Aarhus C, Denmark Business: Renal Hired: Hans Schambye as CEO, formerly CEO of Gastrotech Pharma A/S...
BioCentury | Jun 26, 2006
Company News

Bioscience Managers Ltd., Nordic Biotech K/S deal

...play CuraLogic A/S (CSE:CUR, Copenhagen, Denmark); dermatology company Forward Pharma A/S (Copenhagen, Denmark); gastrointestinal company Gastrotech Pharma A/S...
BioCentury | Jun 26, 2006
Finance

Portfolio plucking

...5/31/06) Forward Pharma Developing immunomodulatory compounds for a range of disorders, particularly in dermatology NA Gastrotech...
BioCentury | Jun 20, 2006
Financial News

BioScience Managers, Nordic Biotech portfolio deal

...LifeCycle (Horsholm, Denmark); allergy play CuraLogic (CSE:CUR); dermatology company Forward Pharma (Copenhagen, Denmark); gastrointestinal company Gastrotech...
BioCentury | Mar 13, 2006
Product Development

Ghrelin pipeline

...Ghrelin pipeline Company Product Description Indication Status/Milestone Gastrotech Pharma GTP-200 Ghrelin analog Cancer cachexia Ph II...
BioCentury | Feb 13, 2006
Clinical News

GTP-200: Phase II started

...daily injections of 1 of 2 doses of GTP-200 for a total of 8 weeks. Gastrotech Pharma A/S...
BioCentury | Nov 7, 2005
Company News

Dor BioPharma, Gastrotech deal

...Dor BioPharma Inc. (DOR), Miami, Fla. Gastrotech Pharma A/S , Copenhagen, Denmark Business: Gastrointestinal, Transplant, Metabolic DOR signed...
...Copenhagen, Denmark Business: Gastrointestinal, Transplant, Metabolic DOR signed a letter of intent to acquire Gastrotech...
...million in stock. DOR plans to issue 20-30 million shares at prices ranging from $0.30-$0.45. Gastrotech...
BioCentury | Oct 28, 2005
Financial News

First closing of new Nordic Biotech fund

...and infectious disease company LifeCycle (Horsholm, Denmark); allergy vaccine company CuraLogic (Copenhagen, Denmark); gastrointestinal company Gastrotech...
Items per page:
1 - 10 of 21
BioCentury | Feb 18, 2008
Strategy

Functional GI compounds

...serotonin (5-HT4) receptor agonist/(5-HT3) receptor antagonist Serotonin (5-HT3) receptor; serotonin (5-HT4) receptor IBS Ph II Gastrotech/Eli...
BioCentury | Feb 4, 2008
Company News

Gastrotech, Eli Lilly deal

...Lilly granted Gastrotech exclusive, worldwide rights to GTP-010 to treat irritable bowel syndrome (IBS) and functional...
...undisclosed equity stake in Gastrotech and is eligible for royalties. Further terms were not disclosed. Gastrotech Pharma A/S...
BioCentury | Sep 4, 2006
Company News

ReceptIcon management update

...ApS , Aarhus C, Denmark Business: Renal Hired: Hans Schambye as CEO, formerly CEO of Gastrotech Pharma A/S...
BioCentury | Jun 26, 2006
Company News

Bioscience Managers Ltd., Nordic Biotech K/S deal

...play CuraLogic A/S (CSE:CUR, Copenhagen, Denmark); dermatology company Forward Pharma A/S (Copenhagen, Denmark); gastrointestinal company Gastrotech Pharma A/S...
BioCentury | Jun 26, 2006
Finance

Portfolio plucking

...5/31/06) Forward Pharma Developing immunomodulatory compounds for a range of disorders, particularly in dermatology NA Gastrotech...
BioCentury | Jun 20, 2006
Financial News

BioScience Managers, Nordic Biotech portfolio deal

...LifeCycle (Horsholm, Denmark); allergy play CuraLogic (CSE:CUR); dermatology company Forward Pharma (Copenhagen, Denmark); gastrointestinal company Gastrotech...
BioCentury | Mar 13, 2006
Product Development

Ghrelin pipeline

...Ghrelin pipeline Company Product Description Indication Status/Milestone Gastrotech Pharma GTP-200 Ghrelin analog Cancer cachexia Ph II...
BioCentury | Feb 13, 2006
Clinical News

GTP-200: Phase II started

...daily injections of 1 of 2 doses of GTP-200 for a total of 8 weeks. Gastrotech Pharma A/S...
BioCentury | Nov 7, 2005
Company News

Dor BioPharma, Gastrotech deal

...Dor BioPharma Inc. (DOR), Miami, Fla. Gastrotech Pharma A/S , Copenhagen, Denmark Business: Gastrointestinal, Transplant, Metabolic DOR signed...
...Copenhagen, Denmark Business: Gastrointestinal, Transplant, Metabolic DOR signed a letter of intent to acquire Gastrotech...
...million in stock. DOR plans to issue 20-30 million shares at prices ranging from $0.30-$0.45. Gastrotech...
BioCentury | Oct 28, 2005
Financial News

First closing of new Nordic Biotech fund

...and infectious disease company LifeCycle (Horsholm, Denmark); allergy vaccine company CuraLogic (Copenhagen, Denmark); gastrointestinal company Gastrotech...
Items per page:
1 - 10 of 21